NeoGenomics to raise capital

FORT MYERS — Cancer-testing firm NeoGenomics says it plans to offer more stock to the public to fund its future growth.

The Fort Myers-based company has not yet specified how much stock it plans to sell or at what price. The company's shares are traded on the Nasdaq (symbol: NEO; recent price: $4.97).

“We intend to use the net proceeds for working capital, capital expenditures and other corporate purposes, including potential acquisitions,” NeoGenomics says in a prospectus filed with the Securities and Exchange Commission. “The company may also use proceeds to repay debt, although at this time no decision has been made to the amount or timing of repayment.”